Long-Term Immune Consequences of Initial SARS-CoV-2 A.23.1 Exposure: A Longitudinal Study of Antibody Responses and Cross-Neutralization in a Ugandan Cohort

Overview

Journal Vaccines (Basel)

Date 2025 Feb 26

PMID 40006690

Authors

Gerald Kevin Oluka

Jackson Sembera

Joseph Ssebwana Katende

Violet Ankunda

Laban Kato

Ashwini Kurshan

Carl Graham

Jeffrey Seow

Katie J Doores

Michael H Malim

Julie M Fox

Pontiano Kaleebu

Jennifer Serwanga

Affiliations

Soon will be listed here.

Abstract

This study assessed the long-term dynamics of neutralizing antibodies in a Ugandan cohort primarily exposed to the A.23.1 SARS-CoV-2 variant, examining how this shaped immune breadth and potency against diverse strains following infection and prototype-based vaccination. We conducted a 427-day retrospective analysis of 41 participants across multiple SARS-CoV-2 waves, assessing binding and neutralizing antibody responses using in-house ELISA and pseudotyped virus neutralization assays. We quantified immune responses to key SARS-CoV-2 variants, A.23.1, D614G, Delta, and BA.4, capturing evolving immunity across the pandemic. Neutralizing antibody titers against A.23.1 remained significantly higher than those against D614G, Delta, and BA.4, highlighting the solid immune memory following A.23.1 infection. Consistently lower titers were observed for BA.4 across all time points, aligning with its strong immune-evasion capability. Correlations between neutralizing titers and spike-directed IgG (S-IgG) concentrations were significantly stronger for A.23.1 than for D614G, with no correlation for BA.4. ChAdOx1-S vaccination substantially elevated the neutralizing titers across all variants, most notably BA.4, highlighting the essential role of vaccination in boosting immunity, even in individuals with initially low titers. Initial exposure to the A.23.1 variant triggered potent immune responses, shaping neutralizing antibody dynamics during subsequent exposures. These findings highlight the importance of accounting for early viral exposures in vaccine development and public health planning. The distinctly lower immune response to BA.4 highlights the need for continuous antigenic monitoring and timely vaccine updates for protection against emerging variants. Vaccination remains essential for reinforcing and sustaining immunity against evolving variants.

References

Lubinski B, Frazier L, Phan M, Bugembe D, Cunningham J, Tang T . Spike Protein Cleavage-Activation in the Context of the SARS-CoV-2 P681R Mutation: an Analysis from Its First Appearance in Lineage A.23.1 Identified in Uganda. Microbiol Spectr. 2022; 10(4):e0151422. PMC: 9430374. DOI: 10.1128/spectrum.01514-22. View

Bekliz M, Adea K, Vetter P, Eberhardt C, Hosszu-Fellous K, Vu D . Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. Nat Commun. 2022; 13(1):3840. PMC: 9253337. DOI: 10.1038/s41467-022-31556-1. View

Johnston T, Li S, Painter M, Atkinson R, Douek N, Reeg D . Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants. Immunity. 2024; 57(4):912-925.e4. DOI: 10.1016/j.immuni.2024.02.017. View

Jawad B, Adhikari P, Podgornik R, Ching W . Impact of BA.1, BA.2, and BA.4/BA.5 Omicron mutations on therapeutic monoclonal antibodies. Comput Biol Med. 2023; 167:107576. DOI: 10.1016/j.compbiomed.2023.107576. View

Cao Y, Jian F, Xiao T, Song W, Yisimayi A, Huang W . Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022; 602(7898):657-663. PMC: 8866119. DOI: 10.1038/s41586-021-04385-3. View

Guo H, Ha S, Botten J, Xu K, Zhang N, An Z . SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies. Viruses. 2024; 16(5). PMC: 11125895. DOI: 10.3390/v16050697. View

Bayas J, Vilella A, Bertran M, Vidal J, Batalla J, Asenjo M . Immunogenicity and reactogenicity of the adult tetanus-diphtheria vaccine. How many doses are necessary?. Epidemiol Infect. 2002; 127(3):451-60. PMC: 2869770. DOI: 10.1017/s095026880100629x. View

Madhi S, Baillie V, Cutland C, Voysey M, Koen A, Fairlie L . Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021; 384(20):1885-1898. PMC: 7993410. DOI: 10.1056/NEJMoa2102214. View

Seow J, Jefferson G, Keegan M, Yau Y, Snell L, Doores K . Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting. PLoS Pathog. 2024; 20(11):e1012724. PMC: 11611254. DOI: 10.1371/journal.ppat.1012724. View

10.

Bugembe D, Phan M, Ssewanyana I, Semanda P, Nansumba H, Dhaala B . Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda. Nat Microbiol. 2021; 6(8):1094-1101. PMC: 8318884. DOI: 10.1038/s41564-021-00933-9. View

11.

Starr T, Greaney A, Addetia A, Hannon W, Choudhary M, Dingens A . Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021; 371(6531):850-854. PMC: 7963219. DOI: 10.1126/science.abf9302. View

12.

Zimmermann P, Curtis N . Factors That Influence the Immune Response to Vaccination. Clin Microbiol Rev. 2019; 32(2). PMC: 6431125. DOI: 10.1128/CMR.00084-18. View

13.

Laing N, Mylan S, Parker M . Does epidemiological evidence support the success story of Uganda's response to COVID-19?. J Biosoc Sci. 2024; :1-8. PMC: 7616485. DOI: 10.1017/S0021932024000117. View

14.

Monto A, Malosh R, Petrie J, Martin E . The Doctrine of Original Antigenic Sin: Separating Good From Evil. J Infect Dis. 2017; 215(12):1782-1788. PMC: 5853211. DOI: 10.1093/infdis/jix173. View

15.

Degryse J, Maas E, Lassauniere R, Geerts K, Kumpanenko Y, Weynand B . Antigenic Imprinting Dominates Humoral Responses to New Variants of SARS-CoV-2 in a Hamster Model of COVID-19. Microorganisms. 2025; 12(12. PMC: 11678355. DOI: 10.3390/microorganisms12122591. View

16.

Reynolds C, Pade C, Gibbons J, Butler D, Otter A, Menacho K . Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021; . PMC: 8168614. DOI: 10.1126/science.abh1282. View

17.

Liang C, Raju S, Liu Z, Li Y, Arunkumar G, Case J . Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature. 2024; 630(8018):950-960. PMC: 11419699. DOI: 10.1038/s41586-024-07539-1. View

18.

Mugitani A, Ito K, Irie S, Eto T, Ishibashi M, Ohfuji S . Immunogenicity of the trivalent inactivated influenza vaccine in young children less than 4 years of age, with a focus on age and baseline antibodies. Clin Vaccine Immunol. 2014; 21(9):1253-60. PMC: 4178574. DOI: 10.1128/CVI.00200-14. View

19.

Bbosa N, Ssemwanga D, Namagembe H, Kiiza R, Kiconco J, Kayiwa J . Rapid Replacement of SARS-CoV-2 Variants by Delta and Subsequent Arrival of Omicron, Uganda, 2021. Emerg Infect Dis. 2022; 28(5):1021-1025. PMC: 9045417. DOI: 10.3201/eid2805.220121. View

20.

Khateeb J, Li Y, Zhang H . Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit Care. 2021; 25(1):244. PMC: 8274962. DOI: 10.1186/s13054-021-03662-x. View